Abstract
Canavan disease is inherited as an autosomal recessive trait that is caused by the deficiency of aspartoacylase (ASPA). The majority of patients with Canavan disease are from an Ashkenazi Jewish background. Mutations in ASPA that lead to loss of enzymatic activity have been identified, and E285A and Y231X are the two predominant mutations that account for 97% of the mutant chromosomes in Ashkenazi Jewish patients. The current study was aimed at finding the molecular basis of Canavan disease in 25 independent patients of non-Jewish background. Eight novel and three previously characterized mutations accounted for 80% (40/50) of mutant chromosomes. The A305E missense mutation accounted for 48% (24/50) of mutant chromosomes in patients of western European descent, while the two predominant Jewish mutations each accounted for a single mutant chromosome. The eight novel mutations identified included 1- and 4-bp deletions (32 deltaT and 876 deltaAGAA, respectively) and I16T, G27R, D114E, G123E, C152Y, and R168C missense mutations. The homozygous 32 deltaT deletion was identified in the only known patient of African-American origin with Canavan disease. The heterozygosity for 876 deltaAGAA mutation was identified in three independent patients from England. Six single-base changes leading to missense mutations were identified in patients from Turkey (D114E, R168C), The Netherlands (I16T), Germany (G27R), Ireland (C152Y), and Canada (G123E). A PCR-based protocol is described that was used to introduce mutations in wild-type cDNA. In vitro expression of mutant cDNA clones demonstrated that all of these mutations led to a deficiency of ASPA and should therefore result in Canavan disease.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Elpeleg O. N., Anikster Y., Barash V., Branski D., Shaag A. The frequency of the C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel. Am J Hum Genet. 1994 Aug;55(2):287–288. [PMC free article] [PubMed] [Google Scholar]
- Kaul R., Balamurugan K., Gao G. P., Matalon R. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution. Genomics. 1994 May 15;21(2):364–370. doi: 10.1006/geno.1994.1278. [DOI] [PubMed] [Google Scholar]
- Kaul R., Gao G. P., Aloya M., Balamurugan K., Petrosky A., Michals K., Matalon R. Canavan disease: mutations among Jewish and non-Jewish patients. Am J Hum Genet. 1994 Jul;55(1):34–41. [PMC free article] [PubMed] [Google Scholar]
- Kaul R., Gao G. P., Balamurugan K., Matalon R. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat Genet. 1993 Oct;5(2):118–123. doi: 10.1038/ng1093-118. [DOI] [PubMed] [Google Scholar]
- Kaul R., Gao G. P., Michals K., Whelan D. T., Levin S., Matalon R. Novel (cys152 > arg) missense mutation in an Arab patient with Canavan disease. Hum Mutat. 1995;5(3):269–271. doi: 10.1002/humu.1380050313. [DOI] [PubMed] [Google Scholar]
- Kronn D., Oddoux C., Phillips J., Ostrer H. Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population. Am J Hum Genet. 1995 Nov;57(5):1250–1252. [PMC free article] [PubMed] [Google Scholar]
- Matalon R., Michals K., Kaul R. Canavan disease: from spongy degeneration to molecular analysis. J Pediatr. 1995 Oct;127(4):511–517. doi: 10.1016/s0022-3476(95)70105-2. [DOI] [PubMed] [Google Scholar]
- Matalon R., Michals K., Sebesta D., Deanching M., Gashkoff P., Casanova J. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet. 1988 Feb;29(2):463–471. doi: 10.1002/ajmg.1320290234. [DOI] [PubMed] [Google Scholar]
- Shaag A., Anikster Y., Christensen E., Glustein J. Z., Fois A., Michelakakis H., Nigro F., Pronicka E., Ribes A., Zabot M. T. The molecular basis of canavan (aspartoacylase deficiency) disease in European non-Jewish patients. Am J Hum Genet. 1995 Sep;57(3):572–580. [PMC free article] [PubMed] [Google Scholar]